Bifogade filer
Quarterly Report Q1 2026
Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
During the quarter, ZymIQ strengthened its international presence through new distribution agreements and participation in leading defense and security fairs in Europe. At the same time, the Biopharma business has taken important steps forward, both organizationally and scientifically, with a focus on building a strong foundation for the next phase of growth.
1 Jan – 31 Mar 2026
· Net sales increased to SEK 835 thousand (812)
· Loss after tax amounted to SEK -3,626 thousand (-2,063)
· Earnings per share amounted to SEK -0.39 (–0.24)
· Cash and cash equivalents amounted to SEK 522 thousand (2,257)
Significant events during the reporting period
· ZymIQ has signed an exclusive distribution agreement for Kalzyme® with the Philippine company Broadchem Philippines BioPharma Corp., one of Southeast Asia's fastest growing animal health markets.
· CombatClean exhibited at Enforce Tac in Nuremberg – one of Europe's leading trade fairs for security and defence – together with Kynotec GmbH and Meier Medizintechnik.
· CombatClean was also represented at the Meeting Place for Civil Protection in Stockholm, a central meeting place for actors in total defence and civil preparedness in Sweden.
· Dr. Mats Clarsund presented ZymIQ Biopharma's research on engineered phage lysins against mycobacteria at the Gordon Research Conference (GRC) in Lucca, Italy – one of the world's most prestigious forums in microbiology and antibiotic resistance.
· Karin Bryder, PhD, has been appointed Chief Operating Officer (COO) of the subsidiary ZymIQ Biopharma AB.